Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the basic materials company’s stock.

RKDA has been the topic of a number of other reports. HC Wainwright reissued a buy rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st. Lake Street Capital raised Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th.

Arcadia Biosciences Stock Down 2.7 %

NASDAQ RKDA opened at $2.78 on Wednesday. The stock’s 50 day moving average is $2.89 and its 200 day moving average is $2.67. The firm has a market capitalization of $3.78 million, a PE ratio of -0.54 and a beta of 1.34. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $4.32.

Arcadia Biosciences (NASDAQ:RKDA) last released its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same period in the prior year, the company earned ($2.64) earnings per share. On average, research analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.